{"@type": "dcat:Dataset", "accessLevel": "public", "bureauCode": ["009:20"], "contactPoint": {"@type": "vcard:Contact", "fn": "CDC Info", "hasEmail": "mailto:ddtpubsmailbox@cdc.gov"}, "description": "VEHSS Composite Prevalence Estimates\n2017, 2019, 2021, 2022. This dataset contains estimates of the prevalence of visual acuity loss and major eye diseases generated using a Bayesian meta-analytic modeling approach that combines information from multiple data sources to produce comprehensive estimates of prevalence by age, race, and gender at the national, state and county levels. These composite prevalence estimates are the primary surveillance measures developed by the Centers for Disease Control and Prevention\u2019s Vision & Eye Health Surveillance System (VEHSS).  \n\nFor more information about these estimates including summary tables and maps, methods, and links to related publications visit https://www.cdc.gov/visionhealth/vehss/estimates/index.html\nTo view this data in the VEHSS interactive data visualization application, visit https://ddt-vehss.cdc.gov/ and search for \u201cVEHSS Composite Prevalence Estimate\u201d.\n\n\nVisual Acuity Loss:\nVisual acuity loss prevalence estimates represent best-corrected visual acuity in the better-seeing eye and are included in rows where Category=\u2019Measured Visual Acuity\u2019.  Rows with Subgroup = \u2018Any vision loss' represents any impairment or blindness of 20/40 or worse; rows with Subgroup = 'US-defined blindness' refers to the subset of vision loss that is 20/200 or worse.\n\n\nAge Related Macular Degeneration:\nThe age-related macular degeneration (AMD) estimates represent AMD as measured with retinal imaging examination, and are included in rows where Category = \u2018Age Related Macular Degeneration\u2019.  The Subgroup \u2018Vision threatening AMD\u2019 includes patients with geographic atrophy, wet-form AMD, or choroidal neovascularization in either eye. The Subgroup \u2018Non-vision threatening AMD\u2019 includes patients with early or intermediate dry-form AMD defined as retinal pigment epithelium abnormalities or drusen \u2265125 \u00b5m in the worse-affected eye, and do not have vision threatening AMD.\n\n\nDiabetic Retinopathy:\nThe diabetic retinopathy (DR) estimates represent DR as measured with retinal imaging examination, and are included in rows where Category=\u2019Diabetic Eye Diseases\u2019.  The Subgroup \u2018Vision threatening DR\u2019 includes patients with severe non-proliferative DR, proliferative DR, and diabetic macular edema. The Subgroup \u2018Non-vision threatening DR\u2019 is defined as patients with mild-moderate non-proliferative DR or unspecified DR, and do not have vision threatening DR.\n\n\nGlaucoma:\nThe glaucoma estimates represent glaucoma as measured with retinal imaging examination and are included in rows where Category=\u2019Glaucoma\u2019. The Subgroup \u2018Vision affecting glaucoma\u2019 includes people with glaucoma and abnormal visual field. The Subgroup \u2018Non-vision affecting glaucoma\u2019 is defined as people with glaucoma without an abnormal visual field.\n\n\nAge Groups:\nThe VEHSS Composite Prevalence Estimates are available by major age groups (All ages, ages 0-17, 18-39, 40-64, 65-84, 85+) and detailed (5-year) age groups, which are indicated by the text \u201cby detailed age groups\u201d in the \u2018Indicator\u2019 field. \n\n\nPrevalence Data Type:\nThese estimates are also available as crude (Data_Value_Type = \u2018Crude Prevalence\u2019) or adjusted data (Data_Value_Type=\u2019Adjusted Prevalence).  Crude Prevalence is the estimate of the actual number and percentage of people living with each condition.  Adjusted Prevalence estimates are adjusted to match the national population by age, race/ethnicity, and gender.  Adjusted prevalence estimates can be used to help identify disparities in prevalence between geographic areas that are not explained by differences in demographic characteristics.\n\n  \nData Sources:\nData sources for VEHSS Composite Prevalence Estimates include the National Health and Nutrition Examination Survey (NHANES), the American Community Survey (ACS), the National Survey of Children\u2019s Health (NSCH), the Behavioral Risk Factor Surveillance System (BRFSS), Medicare Fee-For-Service claims, the Transformed Medicaid Statistical Information System, MarketScan commercial insurance", "distribution": [{"@type": "dcat:Distribution", "downloadURL": "https://data.cdc.gov/api/v3/views/qeru-k2y2/export.csv?accessType=DOWNLOAD", "mediaType": "text/csv"}, {"@type": "dcat:Distribution", "downloadURL": "https://data.cdc.gov/api/v3/views/qeru-k2y2/export.kml?accessType=DOWNLOAD", "mediaType": "application/vnd.google-earth.kml+xml"}, {"@type": "dcat:Distribution", "downloadURL": "https://data.cdc.gov/api/v3/views/qeru-k2y2/export.kmz?accessType=DOWNLOAD", "mediaType": "application/vnd.google-earth.kmz"}, {"@type": "dcat:Distribution", "downloadURL": "https://data.cdc.gov/api/v3/views/qeru-k2y2/query.geojson?accessType=DOWNLOAD", "mediaType": "application/geo+json"}, {"@type": "dcat:Distribution", "downloadURL": "https://data.cdc.gov/api/v3/views/qeru-k2y2/query.json?accessType=DOWNLOAD", "mediaType": "application/json"}, {"@type": "dcat:Distribution", "downloadURL": "https://data.cdc.gov/api/v3/views/qeru-k2y2/query.xml?accessType=DOWNLOAD", "mediaType": "application/xml"}], "identifier": "https://data.cdc.gov/api/views/qeru-k2y2", "issued": "2026-08-11", "keyword": ["blind", "blindness", "prevalence", "vision", "visual"], "landingPage": "https://www.cdc.gov/visionhealth/vehss/estimates/amd-prevalence.html", "license": "http://opendefinition.org/licenses/odc-odbl/", "modified": "2026-08-11", "programCode": ["009:020"], "publisher": {"@type": "org:Organization", "name": "Centers for Disease Control and Prevention"}, "references": ["https://www.cdc.gov/vision-health-data/prevalence-estimates/index.html"], "theme": ["Vision & Eye Health"], "title": "VEHSS Modeled Estimates"}